News & Events about Krystal Biotech Inc.
NEW PDUFA DATE OF MAY 19, 2023PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration(FDA) notified the Company that based on manufacturing information submitted to the Agency on ...
Krystal Biotech, Inc. (NASDAQ:KRYS Get Rating) insider Suma Krishnan sold 1,700 shares of the firms stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $80.33, for a total value of $136,561.00. Following the sale, the insider now directly owns 1,...
Globe Newswire
2 months ago
PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5th Annual ...
Krystal Biotech (NASDAQ:KRYS Get Rating) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $71.00 price target on the stock. Zacks Investment Researchs price objective indicates a potential ...
Ticker Report
9 months ago
Krystal Biotech (NASDAQ:KRYS Get Rating) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $71.00 price target on the stock. Zacks Investment Research&#...